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Abstract
Gastric stem cells have been recently identified and are not yet fully characterized. Each 
gastric gland or unit is composed of different specialized cells and a small number of 
discrete stem cells. These gastric stem cells play key roles. They have self-renewal and 
multipotent properties and are the origin of specialized gastric epithelial cells. These 
properties are the basis for the stem cells’ role in tissue homeostasis, tissue repair, and 
cancer. In tumors, growing evidence indicates that a cell subpopulation with stem cell 
features, the so-called cancer stem cells (CSCs), represents the “fuel” for the tumor: they 
are at the origin of tumor initiation, growth, and dissemination, and they also display 
resistance to conventional chemotherapy treatments. The recent identification of CSCs 
in gastric carcinoma opens the door to the development of new therapeutic strategies 
targeting more specifically the CSCs at the origin of the disease, which is the third leading 
cause of cancer-related deaths worldwide.
Keywords: stem cells, gastric cancer stem cells, CD44, stomach cancer, Helicobacter 
pylori, chemoresistance, ALDH, markers
1. Introduction
Gastric cancer is the third leading cause of cancer-related deaths and the fifth most frequent 
cancer worldwide. The cancer in its nonmetastatic form is essentially treated by surgery asso-
ciated with conventional chemotherapy or by chemotherapy alone when metastatic. Its poor 
prognosis, with less than 10% survival, is due to frequent relapses in metastatic forms even 
after multimodal therapy. This relapse is associated with the persistence of a cell subpopula-
tion that has acquired or possesses intrinsic mechanisms to resist chemotherapeutic drugs. 
Indeed, gastric carcinoma, as other solid tumors, is heterogeneous and, a part of their cell pop-
ulation, the gastric cancer stem cells (GCSCs) are responsible for tumor initiation, progression, 
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recurrence, and metastasis. Herein, we first review the major markers of stem/progenitor cells 
in the stomach, then we describe the cells at the origin of gastric tumors, and finally, we focus 
on the characterization of the GCSC subpopulation.
2. Existence of stem cells in the stomach
In the stomach, the gastric epithelium is a physiologically self-renewing tissue with a cycle of 
2–7 days. Anatomically, the stomach is divided into three main parts: the cardiac region (in 
humans) or the forestomach (in mice), the main body (corpus), and the distal part (antrum/
pylorus). The mucosa of the stomach is composed of a glandular epithelium with millions 
of gastric units. Each gland is considered to be monoclonal [1] and is subdivided into the 
foveolus, isthmus, neck, and bottom regions (Figure 1). In the gastric corpus, the glands are 
long and, from the bottom to the top of the gland, contain zymogenic/chief cells implicated 
in digestion, parietal cells that are essential for acid production, enterochromaffin-like cells 
that control acid production, mucous neck cells, and superficial pit cells. In the antrum, the 
glands are shorter and are composed mainly of mucus-producing cells and enteroendocrine 
hormone-secreting cells that regulate acid and digestive enzyme production in the corpus. In 
both regions, some discrete gastric stem cells exist and are instrumental in stomach epithe-
lium renewal under pathophysiological conditions.
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Figure 1. Architecture of the gastric glands and localization of stem/progenitor cells in the main parts of the stomach. 
(a) Fundic/corpus gastric gland. (b) Antral/pyloric gastric gland. Stem/progenitor markers identified by lineage tracing 
are indicated in bold.
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In adult organs, tissue stem cells are characterized by self-renewal and asymmetrical divi-
sion properties, giving rise after mitosis to another stem cell and to a progenitor cell that will 
undergo expansion and then differentiation into mature cells. These stem cells reside in a 
physiologically limited and specialized microenvironment, called the niche, which is com-
prised of cells and extracellular matrices forming the surrounding stroma (including mesen-
chymal cells, vessels, nerves) and which plays a key role in the maintenance of the stem cell 
number and functions and in preventing tumorigenesis. The localization of the niche of stem/
progenitor cells varies according to the part of the stomach considered: in the corpus, they 
are located in the isthmus just below the glandular narrowing, and in the antropyloric region, 
there are located at the bottom of the glands. Moreover, as is the case in other organs [2], the 
coexistence of two stem cell populations has been described in the stomach: (1) a population 
of dividing gastric stem cells recruited under “homeostatic conditions”, expressing CD44 or 
Lgr5 markers and (2) a rare population of quiescent cells recruited mainly upon tissue dam-
age, expressing Villin, Troy, and Mist1 markers (Figure 1).
2.1. Discovery of gastric stem cells and their markers
Using radiolabeling experiments and analyses of the cells by electron microscopy, Leblond et al. 
first identified a group of small undifferentiated and granule-free cells with the highest labeling 
index as the putative stem/progenitor cells. These cells are localized in the isthmus region from 
where they migrate toward both the pit and the bottom [3, 4]. However, the first evidence of the 
existence of multipotent stem cells in adult mouse gastric glands was found later using chemi-
cal mutagenesis of single cells and long-term gastric epithelial cell analyses where many clones 
spanned entire glands containing all specialized gastric cell lineages [5]. The use of inducible 
Cre recombinase activity to indelibly label putative stem/progenitor cells and their progeny 
in the stomach has been widely practiced and is considered as the gold standard method for 
lineage tracing studies. The first marker of gastric stem/progenitor cells revealed by lineage 
tracing in the gastric mucosa was Villin. Villin-lacZ transgenic mice revealed a rare population 
of quiescent β-galactosidase-positive cells located at the bottom of antropyloric glands or at 
the isthmus in the corpus [6]. These quiescent Villin+ cells can be activated after stimulation by 
interferon-γ and moved from the isthmus toward the base of the gland to generate all of the 
specialized cells of the gastric glands. Villin+ cells may act as a stem cell reservoir with a high 
proliferative potential to regenerate the gastric mucosa after injury. The presence of such a cell 
population that highly responds to inflammation is very interesting, especially in the context of 
gastric cancer which is initiated by a chronic inflammation of the gastric mucosa.
Leucine-rich G protein-coupled receptor 5 (Lgr5), a well-recognized stem cell maker in the 
intestine, is expressed at the bottom of prospective corpus and pyloric glands in the stomach 
of neonates, whereas its expression in adults is predominantly restricted to the bottom of 
pyloric glands in mice and in humans [7]. Lineage tracing experiments revealed that Lgr5+ 
cells are multipotent stem cells responsible for the long-term renewal of the gastric epithe-
lium. In vitro, single Lgr5+ cells generated long-lived organoids resembling the pyloric epithe-
lium in three-dimensional culture. Lgr5+ cells divide symmetrically to generate clonal gland 
units via neutral competition and lateral expansion of stem cell clones via gland fission under 
non-damaging conditions [8].
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These two markers identified stem cells in the gastric antrum/pyloric region, where most of 
distal gastric carcinoma arises in humans. In the corpus, some studies suggested that Sox2+ 
cells may represent long-lived stem cells scattered throughout the isthmus and in the lower 
part of the gastric unit [9]. Trefoil factor family 2 (Tff2+) cells were also described as short-
lived progenitors in the isthmus region of the corpus [10]. More recently, lineage tracing 
experiments have shown that differentiated mature chief cells expressing the Troy marker at 
the base of the corpus gastric glands can generate entirely labeled gastric units over a period 
of several months in vivo and long-lived organoids in vitro [11]. This phenomenon is acceler-
ated upon depletion of the proliferating isthmus compartment mediated by 5-fluorouracile 
treatment, suggesting that the gastric corpus also seems to contain two stem cell populations: 
(1) an actively dividing population located in the isthmus region and (2) a smaller reserve 
population of Troy+ stem-like chief cells located at the base of the gland [11]. This property of 
a differentiated cell to reenter the cell cycle and to act as a multipotent stem cell highlights the 
plasticity of gastric epithelial cells. Surprisingly, Stange et al. detected Lgr5+ cells at the base of 
the corpus glands using another Lgr5 reporter construction in transgenic mice, and transcrip-
tomic analyses demonstrated that Troy+ cells expresses several Wnt target genes including 
Lgr5 and CD44 [11].
Likewise, Mist1 is a marker of stem-like quiescent chief cells located in the lower third of the 
glands and in rare single cells of the isthmus in the gastric corpus [12, 13]. The vast majority 
of Mist1+ chief cells at the base of the glands are Lgr5+, whereas Mist1+ cells in the isthmus are 
Lgr5−, and only 1.1% of them are proliferative. Ablation of Lgr5+/Mist1+ chief cells by expres-
sion of the diphtheria toxin in Lgr5-DTR-GFP transgenic mice results in an increase of Mist1+ 
cells in the isthmus which reconstitute the entire glands, suggesting that Mist1+ isthmus cells 
are multipotent stem cells [13]. Finally, Mist1+ isthmus cells can form organoids in an Lgr5-
independent manner in the corpus.
In addition, the Runx1 enhancer element, eR1, is expressed in the isthmus and marks a small 
number of terminally differentiated chief cells at the base in the stomach corpus as well as 
near the bottom of the pyloric gland. eR1+ cells generated entirely labeled gastric units after a 
year and formed organoids in vitro, suggesting that they are composed of gastric stem cells 
[14]. Nevertheless, it appears that some Runx1-expressing cells are stem cells, whereas others 
are differentiated cells, such as pit cells. Moreover, 80% of eR1+ cells expressed Ki67, whereas 
only 1.1% of Mist1+ cells in the isthmus expressed it, suggesting that Mist1+ cells are quiescent 
cells and that eR1+ cells are rapidly dividing cells [13, 14].
Additional markers have been proposed for gastric stem cells (e.g., DCKL1/DCAMKL1, 
CD133/PROM1, and CD44), but the multipotency of these cells has not yet been analyzed 
by lineage tracing [15, 16]. Khurana et al. found that CD44 (cluster of differentiation 44) is 
mainly expressed at the base of antral/pyloric glands, in a region overlapping Lgr5, and in 
the isthmus region of the corpus glands [17, 18]. When parietal cell loss and atrophy were 
induced chemically or by Helicobacter infection, the CD44+ cells expanded from the isthmus 
and replenished the base of the gastric units (Figure 2). CD44 expression is enriched in the 
Mist1+ isthmus stem cell population in the corpus, suggesting again that they could represent 
stem/progenitor cells.
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2.2. Factors sustaining gastric stem cell self-renewal and multipotency
Until very recently, suitable models to study gastric stem cells in vitro were lacking. Cell lines 
from cell banks are all derived from carcinomas, and primary culture of gastric epithelial 
cells from biopsies is not successful under conventional adherent culture conditions. Culture 
of antrum and fundus cells has been rendered possible very recently by the development of 
mouse and human protocols allowing the development of organoids, named gastroids, under 
three-dimensional culture conditions, in media containing epithelial growth factor (EGF) 
and Noggin, with either Wnt3A and R-spondin, a molecule binding Lgr4/5 and potentiating 
Wnt/β-catenin activity [19], or supplemented with the Notch ligand Jagged-1 [7, 13]. In vitro 
studies of organoid formation by gastric stem cells or gastric glands have allowed insight 
in the necessary growth factors and signaling molecules of the niche implicated in stem cell 
properties and gland formation and can offer new therapeutic applications in patient that 
suffer malignant diseases, for example, for ulcer treatment. Engevik et al. have shown that 
gastric stem cells/organoid isolated from young mice can be transplanted into sites of ace-
tic acid-induced ulcer within the stomachs of older mice and that this results in accelerated 
repair injury [20].
Wnt5a, a noncanonical Wnt ligand, is highly expressed by Cxcr4+ cells in the isthmus part of the 
corpus. Histological analyses show that Wnt5A is secreted by Cxcr4+ resident hematopoietic 
Non-infected Metaplasia Dysplasia
H. pylori
a b c
Figure 2. CD44 expression in H. pylori-induced metaplasia and dysplasia. Representative pictures of CD44 detection 
by immunohistochemistry in mouse stomachs: (a) normal gastric mucosa of a noninfected mouse; (b) metaplasia; and 
(c) intraepithelial dysplasia in H. pylori SS1-infected stomachs. Scale bars, 50 μm.
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cells recruited to the isthmus and stimulated by Cxcl12 endothelial cell production. The effi-
ciency of organoid formation is enhanced by Wnt5a or coculture with Cxcr4+ intraepithelial 
gastric innate lymphoid cells [13], suggesting that cells in the niche regulate stem/progenitor 
proliferation.
The enteric nervous system also has the ability to regulate gastric homeostasis via direct inner-
vation of the glands. In three independent mouse models of gastric cancer, Zhao et al. elegantly 
demonstrated that surgical or pharmacological denervation suppresses gastric tumorigenesis, 
even if performed at an early preneoplastic step [21]. Further analyses revealed that choliner-
gic nerves surround the base of glands and modulate epithelial stem cells through activation 
of the Wnt signaling pathway via the muscarinic acetylcholine receptor 3 (M
3
R) expressed by 
Lgr5+ cells. In stomach organoid models, coculture with neurons or treatment with pilocar-
pine, a cholinomimetic drug, increased organoid formation and the expression of Lgr5 and 
Cd44 stem cell markers, whereas the effects were reversed by botox treatment [21]. Another 
publication reported that Dclk1+ tuft cells and nerves, the main sources of acetylcholine in the 
gastric mucosa, induced nerve growth factor (NGF) secretion from epithelial cells that expand 
enteric nerves and promote carcinogenesis [22]. Remarkably, Tff2-Cre;R29-NGF mice devel-
oped metaplasia and dysplasia by 8 months of age with CD44+ dysplastic cell expansion and 
intramucosal adenocarcinomas by 18 months. Ablation of Dclk1+ cells in this context led to 
the inhibition of epithelial proliferation and tumorigenesis in a M
3
R-dependent manner [22].
The Notch signaling pathway is also inhibited in vagotomized mice [21]. The Notch inhibitor 
dibenzazepine (DBZ) reduced the proliferation in the isthmus region, decreased the Mist1-
lineage tracing, and blocked the growth of corpus organoids in vitro, suggesting that Notch 
activity is important for corpus gastric stem cell maintenance and activity [13].
3. Is gastric cancer a stem cell disease?
Gastric carcinoma is a multifactorial disease, involving a chronic Helicobacter pylori infection 
as the main cause as well as the Epstein-Barr Virus to a small extent, diet (low vitamins, 
nitrosamines, chemicals, etc.), smoking, and genetic susceptibility of the host [23, 24]. At the 
histological level, the WHO described more than five different histological subtypes, divided 
into two main groups in the Lauren classification of gastric tumors, i.e., the intestinal type 
and the diffuse type [25]. At the molecular level, gastric carcinomas are classified in four main 
groups based on their mutational profile [26, 27]. These classifications are not currently used 
in clinical practice to orientate toward a specific targeted therapy.
More than 93% of distal gastric carcinoma cases are associated with a chronic H. pylori infec-
tion of the gastric mucosa [28]. Most of these cases represent the intestinal histological sub-
type. H. pylori infection induces a chronic inflammation of the gastric mucosa, i.e., gastritis. 
In 5–10% of cases, gastritis evolves into gastric or duodenal ulcer, and in 1% of cases, gastritis 
leads to stomach cancers. In this last case, the loss of specialized epithelial cells results in a 
chronic atrophic gastritis and to the compensatory cellular hyperproliferation and aberrant 
differentiation at the origin of the intestinal metaplasia (firstly appearing in the pylorus) 
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and/or spasmolytic polypeptide-expressing metaplasia (SPEM) (mainly in the corpus). These 
metaplastic lesions can further progress into dysplasia and ultimately into an intestinal-type 
carcinoma according to the Lauren classification [29, 30]. So, chronic atrophic gastritis is con-
sidered to be the first step of gastric adenocarcinomas. All of these lesions are well charac-
terized histologically and can be reproduced experimentally in Mongolian gerbils [31] and 
in mice [32, 33] in response to H. pylori and Helicobacter felis infection. Gastric carcinoma of 
the diffuse type or signet ring cell carcinoma corresponds to poorly differentiated adenocar-
cinomas for which the glandular structure has disappeared. It is the second most frequent 
histological subtype of gastric tumors, which is frequently linked to sporadic or hereditary 
mutations of the CDH1 gene encoding E-cadherin, and appears most of the time without 
precancerous lesions.
H. pylori is mainly present at the surface of gastric units but also as microcolonies deep in the 
stomach glands; the bacteria can interact directly with gastric stem/progenitor cells in the 
stomach of mice and humans. Regarding their long lifetime and high division ability, stem 
cells are more susceptible to accumulate genetic/epigenetic modifications than their progeny. 
Some current evidence suggests that, in the context of chronic H. pylori infection, gastric can-
cer stem cells originate from the transformation of stem cells of two different origins: local, for 
most of the cases, and to a lesser extent from bone marrow-derived stem cells that home into 
the gastric mucosa in response to the chronic injury mediated by Helicobacter, contributing to 
metaplasia and dysplasia [34–36]. It is important, however, to distinguish between the origin 
of cancer cells which initiate and drive the primary tumor development and those which 
accumulate and contribute to tumor growth once the process is initiated. These two main 
mechanisms leading to the emergence of gastric cancer cells will be discussed below.
3.1. Tumors can originate from epithelial stem cell transformation
Interestingly, the parietal cell atrophy induced after H. pylori infection causes an increase in the 
proliferation of stem/progenitor cells in the isthmus [37] that is associated with an induction 
of CD44 expression in this region, which then expands toward the bottom of the gastric unit 
[17, 35, 36] (Figure 2). Sigal et al. also reported an increase of the number of antral Lgr5+ cells in 
H. pylori-associated gastritis and carcinoma in humans. As these cells are susceptible to DNA 
damage, it suggests that Lgr5+ stem cells could be at the origin of cancer [38, 39]. An Lgr5+ 
gene signature in pyloric gastric units identified Wnt target genes, including Sox9 and Cd44, 
suggesting canonical Wnt signaling activity at the base of the pyloric glands. Gastric cancer 
patients exhibit a dysregulation of Wnt signaling [21]. Spontaneous Wnt activation in the 
mouse model APCmin leads to the development of gastric adenomas in the pyloric region; Apc 
depletion specifically in Lgr5+ via a single tamoxifen injection in Lgr5-EGFP-CreERT2;APCflox/flox 
mice leads to adenoma formation in the gastric antrum, but not in the corpus [7].
KRAS is one of the most commonly mutated oncogenes in gastric cancer. The Kras mutation 
in the Mist1+ isthmus cells, and not in the Mist1+ chief cells, results in the formation of meta-
plastic/dysplastic foci from the isthmus to the bottom of glands. Mist1+ stem cells give rise 
to intramucosal intestinal-type gastric cancer induced by Apc loss of function but only in the 
context of KRAS-induced metaplasia [13].
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E-cadherin expression is lost in most diffuse-type gastric carcinomas, but E-cadherin loss 
alone is not sufficient to initiate diffuse-type gastric cancer in mice [40]. Loss of the tight 
junction protein IQGAP1 is also insufficient to induce diffuse-type gastric carcinoma in trans-
genic mice after challenge with Helicobacter infection, as it indeed promotes intestinal-type 
carcinogenesis [41]. To try to reproduce the diffuse-type gastric cancer, some authors infected 
Mist1;CreERT2;Cdh1flox/flox mice with H. felis to induce chronic inflammation. In this context, 
E-cadherin loss in Mist1+ cells resulted in the development of diffuse-type gastric carcinomas 
[13]. The double inactivation of E-cadherin and p53 in a conditional mouse model also suc-
cessfully led to metastatic diffuse-type gastric cancer [42].
3.2. Tumors originating from bone marrow-derived cells
Some data have shown that bone marrow-derived cells (BMDCs) can migrate to peripheral 
tissues in case of injury or inflammation where they are engrafted and participate in tissue 
repair, giving rise to all cell lineages. Houghton et al. showed that BMDCs are recruited into 
the gastric mucosa of C57BL/6 mice chronically infected by H. felis and contribute overtime to 
metaplasia, dysplasia, and finally cancer [34]. In fact, to the contrary, they found that it was a 
rare event in the context of a normal homeostasis, without injury. Results from this study did 
not exclude the possibility that BMDCs participate in the development of lesions via fusion 
with epithelial cells. Our group confirmed these observations in the same mouse genetic back-
ground but with different strains of the human pathogen H. pylori and found that nearly a 
quarter of high-grade dysplastic lesions are composed of BMDCs [35]. BMDC epithelial gland 
repopulation was significantly associated with pseudointestinal metaplasia, suggesting that 
BMDC recruitment may play a role in preneoplastic lesion progression. These BMDCs are 
recruited only in response to chronic H. felis and H. pylori infection but not in response to acute 
injury [34]. BMDC recruitment occurs in response to the secretion of several chemokines such 
as SDF1 and TNFα by infected epithelial cells in a NF-κB-dependent manner [34, 43]. Once 
recruited, the BMDCs can differentiate into local gastric epithelial cells via transdifferentiation 
or cell/cell fusion with local gastric epithelial cells [35, 44]. Interestingly, BMDC recruitment 
into the gastric mucosa was a late event in the cascade of gastric carcinogenesis, occurring only 
in infected animals of more than 1 year of age. In these chimera mice, metaplastic lesions were 
comprised, inside the same gland, of a mosaic of tagged-BMDCs and native gastric epithelial 
cells, revealing a multiclonal composition [35]. These metaplastic lesions are now considered 
as a “point of no return,” after which, most of the time, eradication of H. pylori cannot lead to a 
regression of the metaplastic and associated dysplastic lesions, because mutations deregulating 
stem cell properties and proliferation are already present. A monoclonal conversion will occur 
during the evolution of intestinal metaplasia toward dysplasia and finally carcinoma. As the 
mice never develop real metastatic gastric adenocarcinoma in contrast to the human situation, 
there is no evidence in the literature to date of the role of BMDCs composing metaplastic/dys-
plastic lesions as the tumor-initiating cells in invasive gastric adenocarcinoma. However, it is 
very interesting to note that BMDCs were also detected in gastric carcinoma of the esophagus 
in mice models and in humans, which also develop on a background of chronic inflammation 
and intestinal metaplasia cascade [45, 46]. Very few studies have been described in humans to 
strengthen the results obtained in animal models, because there is a limited possibility to trace 
BMDCs in an individual developing a carcinoma of the GI tract. The only technical approach 
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tested was to detect the Y chromosome of BM cells of a male donor in female transplanted 
patients by fluorescence in situ hybridization (FISH). In such transplanted cases having devel-
oped carcinoma of the GI tract, BMDCs were detected in some rare cases of carcinoma and 
dysplasia of the esophagus [45, 46]. Concerning the stomach, the study of Whortley et al., per-
formed on only four cases of sex-mismatch transplanted cases having developed gastric carci-
noma, failed to report a carcinoma composed of cells of BM origin. However, one of the cases 
showed aneuploidy, so a contribution of the BMDCs cannot be totally excluded [47].
Unfortunately, in those models, full proof of the concept that gastric stem cells or other popu-
lations of differentiated cells or BMDCs are the cells of origin of cancer has not been found, 
because the tumorigenic effect mediated, for instance, by Apc and Cdh1 inactivation or by 
Kras oncogenic activation in non-stem cell populations, i.e., in progenitor or differentiated 
cells, has not been followed. Moreover, in contrast to squamous skin tumors [48] or intestinal 
adenomas [49], the in vivo contribution of GCSCs to tumorigenesis has not yet been fully 
elucidated. Nevertheless, regardless of their origin, dysplastic lesions and gastric adenocar-
cinomas are composed of CD44+ cells (Figure 2) [17, 36] that have been recently described to 
possess cancer stem cell properties [50, 51].
3.3. Tumor originates from dedifferentiation of epithelial cells
In an inflammatory setting, differentiated cells can reacquire the ability to divide and to give 
rise to all cell lineages. In vitro, H. pylori infection induces a destabilization of cell/cell junctions 
and an elongated phenotype associated with motility [52]. We reported that H. pylori infection 
leads to the generation of a CD44+ cancer stem-like cell population with mesenchymal pheno-
type and tumorigenic properties, through complex signaling pathways involving activation 
of the mitogen-activated protein kinase ERK, c-Jun N-terminal kinase, miR200, and NF-κB 
signaling pathways, leading to the activation of ZEB1 and Snail1 transcription factors, the 
main drivers of the epithelial-mesenchymal transition (EMT) [36]. We showed that this effect 
was associated with the bacterial oncoprotein CagA produced by H. pylori and with secreted 
factors such as hepatocyte growth factor (HGF) as described by others [36, 53]. In vivo, the 
expansion of the compartment of CD44+ stem cells at the isthmus in the corpus and at the base 
of the glands in the antro-pyloric region is associated with the expression of mesenchymal 
markers in the context of H. pylori-associated gastritis, metaplasia, and dysplasia, in humans 
and in wild-type mice [23, 36, 41]. We recently showed that invalidation of iqgap1, a partner 
of E-cadherin at the cell/cell junctions, increased EMT both in vitro and in vivo, promoted 
H. felis- and H. pylori-induced regenerative hyperplasia expressing CD44 and mesenchymal 
markers, and accelerated and worsened metaplasia and dysplasia development, reinforcing 
the causal link between EMT and emergence of CSC-like cells [41].
4. Properties of gastric cancer stem cells
Tumor cells are heterogeneous in terms of mutations carried, susceptibility to drugs, markers 
expressed or morphology, and not all are tumorigenic. This genetic heterogeneity would come 
not only from intrinsic factors such as genetic mutations acquired progressively and amplified 
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within new clones but also from extrinsic factors related to the variation of the tumor micro-
environment [54, 55]. To explain these observations, two concepts have been proposed: the 
cancer stem cell (CSC) theory, also named the hierarchical model, and the stochastic model. 
In the stochastic model, all cancer cells have similar tumorigenic properties, with cancer aris-
ing after a series of genetic and epigenetic events leading to successive waves of clonal selec-
tions depending on the proliferative and survival benefits acquired. In the hierarchical model, 
there is a cellular hierarchy between cancer cells inside the tumor, with CSCs being at the 
origin of the more or less differentiated cells, not all proliferative and tumorigenic, compos-
ing the tumor mass. CSCs represent a small percentage of tumor cells and possess particular 
properties compared to non-CSCs (Figure 3): (1) the first and most important is their capacity 
to self-renew and divide asymmetrically and to generate a new CSC and a non-CSC pro-
genitor cell, a property that maintains a constant CSC pool; (2) CSCs are able to initiate tumor 
growth when injected in low cell numbers in immunocompromised mice; (3) CSCs display 
differentiation properties giving rise to the more or less differentiated cells composing the 
tumor mass, reconstructing the tumor heterogeneity observed within the primary tumor; (4) 
CSCs have increased resistance to current chemo- and radiotherapies; and (5) CSCs express 
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Figure 3. Hierarchical model illustrating the heterogeneity of the tumors. (a) Representative images of CD44 detection 
by immunohistochemistry on tumor tissue section (left panel) and of the detection of CD44 by immunofluorescence and 
ALDH activity (Aldefluor™ reagent) with Hoescht 33342 dye (middle panel) on tumor spheres of MKN45 gastric cancer 
cells (right panel, phase contrast microscopy). Scale bars, 50 μm. (b) Hypothetical strategies to target CSC to cure gastric 
cancer. The main gastric CSC markers are CD44 and ALDH activity. Cancer stem cells represent a subpopulation of cells 
implicated in tumor initiation, growth, metastasis, and chemo-/radio-resistance.
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specific markers [55]. This hierarchical model is not exclusive but is now the most accepted 
model with the recent identification of CSCs in most cancers since their first discovery in acute 
myeloid leukemia in 1995, then in solid tumors in 2003, and more recently in gastric carci-
noma. However, we must keep in mind that this hierarchical model is also subjected to clonal 
evolution even if it has not been clearly demonstrated for gastric carcinoma [56].
4.1. Functional characterization of gastric cancer stem cells
By taking advantage of the capacity of stem cells to self-renew, differentiate, and initiate tumors, 
functional assays have been developed to evaluate the amount of GCSCs or to isolate them 
from a global population of tumor cells. In vitro, under conditions in which cells are seeded at 
low-density in low-adherent plates, without serum and in the presence of some growth factors 
such as EGF, bFGF, and insulin, only GCSCs can survive, self-renew, and form tumorspheres 
[36, 50, 51, 57]. Long self-renewal ability is evaluated after tumorsphere dissociation into single 
cells and several passages; indeed only GCSCs can generate tumorspheres after several pas-
sages [51, 58]. In vivo, frequency of GCSCs in a given population is determined after subcu-
taneous xenograft in immunocompromised mice using different cell doses and an analysis of 
their ability to initiate a new heterogenous tumor after several weeks. Immunocompromised 
mouse phenotypes, nonobese diabetic/severe combined immunodeficiency (NOD/SCID) and 
NOD/SCID/IL2Rg− (NSG), can influence the CSC frequency as reported in the case of mela-
noma by Morrison’s group [59]. In both methods, cells were seeded for an extreme limiting 
dilution assay, and a mathematical method was applied to calculate the CSC frequency in a 
given cell population [51, 60].
4.2. Phenotypic characterization of gastric cancer stem cells
Several phenotypic characteristics have been proposed to isolate GCSCs using fluorescence-
activated cell sorting (FACS), including (1) the expression of cell membrane markers (or com-
binations of markers), and among them CD44; (2) the exclusion of Hoechst 33342 dye by the 
“side population” of cells (SP cells); and (3) the enzymatic activity of aldehyde dehydroge-
nases (ALDH).
CD44 was among the first markers of CSCs described in solid tumors and initially in breast 
carcinoma [61]. CD44 is a type I transmembrane glycoprotein expressed in many normal and 
tumoral cells. It plays a role in adhesion/homing, supporting cell migration and transmitting 
survival signals, thereby being pro-oncogenic by nature. The principal ligand of the CD44 
receptor coordinating signalization is hyaluronic acid, but it can also interact with additional 
molecules of the extracellular matrix, such as collagen, fibronectin, fibrinogen, laminin, or 
osteopontin [62]. Cytoplasmic partner molecules of CD44 are the cytoskeletal proteins Ezrin, 
Radixin, Moesin, and Ankyrin, which influence the signaling pathway. Loss of CD44 in mice 
models results in a decrease in gastric mucosa proliferation in the isthmus region. The critical 
role of CD44 in proliferation involves its interaction with hyaluronic acid and the downstream 
activation of the STAT3 signaling pathway [17], RhoGTPases, the PI3K/AKT pathway, and the 
MAPK signaling pathway [63]. CD44 is encoded by the 20-exon CD44 gene, in which exons 
1–5 and 16–20 are spliced together and translated into CD44s, the standard or small isoform. 
Gastric Cancer: A Stem Cell Disease?
http://dx.doi.org/10.5772/intechopen.69947
73
In addition, the variant exons 6–15 can be alternatively spliced and assembled in different 
combinations with the standard exons to generate other variant (CD44v) protein isoforms [62, 
64]. We and others reported that CD44 is expressed following H. pylori infection in patients 
and in mouse models in the case of regenerative hyperplasia, intestinal metaplasia, dysplasia, 
and gastric carcinoma (Figure 2) [35, 36, 50, 51, 65]. Histological and molecular analyses of 
tumor collections have shown that CD44 is positively and significantly associated with tumor 
recurrence and mortality in gastric cancer, and the expression of CD44 and CD44v has also 
been associated with metastasis formation [57, 65–70].
Takaishi et al. were the first to propose CD44 as a marker of GCSCs in a study performed 
on several gastric cancer cell lines [50]. Their CD44+ cells were able to form tumorspheres 
and initiate tumors after subcutaneous and orthotopic engraftment in mice, and they were 
resistant to anticancer drugs, whereas CD44− sorted cells were not. Moreover, it seems that 
CD44 is not only a GCSC marker, but it also plays an oncogenic role, assessed by a decrease 
in tumor growth using siRNA targeting CD44. More recently, further relevant results from 
patient-derived xenograft models (PDXs) of gastric carcinoma have confirmed that CD44 
is also a marker of GCSCs in primary gastric carcinoma. The FACS-sorted CD44+ cells, but 
not their CD44− counterpart, displayed CSC properties such as growing as tumorspheres 
in vitro and lead to tumor formation in vivo that reconstitute the heterogeneity of the pri-
mary tumor of the patients and are more chemoresistant [51, 71, 72]. ESA, CD24, CD133, 
and CD166 are also expressed by CD44+ cells, but they do not allow a better enrichment 
of GCSCs in combination with CD44 compared to CD44 alone [51, 73]. Although CD44 
marks GCSCs, not all CD44+ cells are tumorigenic [51]. CD44v8-10, also named CD44E, 
has been identified as the predominant CD44 variant expressed in gastric cancer cells, 
and its expression is low in normal tissues [57]. It plays a functional role in tumor initia-
tion, most likely by increasing CSC resilience to adverse conditions such as hypoxia or 
oxidative stress. Indeed, there is evidence that CD44v8-10 stabilizes the cystine-glutamate 
transporter subunit xCT and promotes the synthesis of glutathione, thereby protecting 
cancer cells from reactive oxygen species [70]. Depletion of the expression of CD44 leads 
to a decrease in the tumorigenicity of cancer cell lines [50], and Yoon et al. demonstrated 
implication of the Hedgehog signaling in the maintenance, chemoresistance, and migra-
tion capacity of the GCSC CD44+ cells [74].
ALDH activity has also been described as a GCSC marker [51, 75]. In an extensive screening 
of the expression of 10 putative CSC surface markers, as well as in eight PDX models, we 
found that CSCs expressed both CD44 and ALDH activity and that ALDH activity revealed a 
subpopulation within the CD44+ cells that possessed CSC properties, i.e., the ability to gener-
ate a new heterogeneous tumor in vivo and a tumorsphere in vitro. Xenograft experiments 
using the ELDA mathematical model showed that the frequency of GCSCs expressing CD44 
and ALDH was 0.1–3.5% of the cancer cells [51]. These CD44+/ALDH+ cells did not incorporate 
the vital DNA dye Hoechst 33342, whereas the ALDH− cells incorporated it, suggesting that 
CD44+/ALDH+ cells may correspond to SP cells with CSC properties as previously described 
in gastric carcinoma cell lines by others [76–78]. The ability of CD44+/ALDH+ cells to efflux 
the Hoechst 33342 dye and to resist conventional chemotherapy was reversed by treatment 
with efflux pump inhibitors [51]. Nevertheless, Takaishi et al. found that both gastric SP and 
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non-SP cells possess a tumorigenic ability in vitro and in vivo [50]. Therefore, the detection of 
the SP cells does not seem to be a good marker for GCSCs; rather the best markers to detect 
them are CD44 and ALDH.
4.3. Missing data: implication of gastric cancer stem cells in metastasis?
Another important property of CSCs is their ability to initiate metastasis. Metastasis is a rare 
event [79] requiring the acquisition of invasive properties through epithelial-mesenchymal 
transition (1) to escape from the niche of the primary tumor in order to disseminate to dis-
tant organs after extravasation as circulating tumor cells (CTCs) and (2) to initiate secondary 
tumors [80]. We reported that the CD44+ cells with CSC-like properties induced by H. pylori 
infection but not the CD44− cells overexpressed mesenchymal markers such as Vimentin and 
Zeb1 and downregulated epithelial markers and tumorigenic, migratory, and invasive prop-
erties [36, 81]. Chen et al. identified CTCs characterized by CD44+CD54+ expression in the 
peripheral blood from patients with gastric cancer which were able to form tumorspheres and 
generate heterogeneous tumors when injected into immunodeficient mice; these CTCs had a 
self-renewal capability both in cell culture and in mouse models [82]. This study suggested 
that CD44+CD54+ CTCs could represent metastatic GCSCs. Nevertheless, the characterization 
of the CSC subpopulation capable of initiating metastases needs to be determined.
5. Conclusion
Since 2007, researchers have increased efforts to identify real gastric stem cells, the cell popu-
lation capable of replenishing an entire gastric gland containing of all cell lineages. Many 
of the markers involved have been reviewed here, and their stemness properties have been 
clearly demonstrated in mouse models. It will be of interest to understand why there are dif-
ferent localizations of stem cells, one in the isthmus and one at the bottom of the gland. These 
two stem/progenitor cell niches could play different roles, one being more proliferative than 
the other one which seems to behave like a reservoir, but they could also play distinct roles in 
response to different stimuli and damage to the gastric mucosa.
Regarding to the gastric tumor, an in-depth analysis of putative CSC markers identified CD44 
as well as ALDH activity as the “gold” gastric CSC markers in cancer cell lines and in PDX 
models [51]. Determination of the signaling pathways controlling their properties is now 
instrumental to find new targeted therapies for gastric cancer, for which there is a crucial 
unmet need to find new efficient therapy. In this aim, we have shown by different strategies 
that the targeting of gastric CSCs expressing CD44 by blocking specific microRNAs or by 
inducing their differentiation by all-trans retinoic acid allows inhibition of tumor growth in 
vivo [58, 83].
Nevertheless, the characterization of gastric CSCs was limited in some publications by the 
cellular model used. To date, the best models to study the efficiency of new therapeutic strate-
gies on primary gastric CSCs remain PDX models, with the restriction that almost all of those 
described are subcutaneous engraftments which never give rise to metastasis. Moreover, 
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mouse models of gastric carcinogenesis induced by Helicobacter infection and/or carcinogens 
do not reproduce invasion of the deeper layers of the stomach, peritoneal carcinomatosis, and 
distant metastases as in humans. Consequently, there is an urgent need to develop mouse 
models of metastatic gastric carcinoma, in order to study the efficiency of new therapeutic 
strategies targeting CSCs not only on tumor initiation but also on metastasis formation.
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